Endocrine Abstracts

Objectives: Endogenous Cushing’s Syndrome (CS) is a rare, chronic condition that results in high morbidity, caused by prolonged exposure to elevated levels of circulating free cortisol levels. Osilodrostat, a newly approved steroidogenesis inhibitor, has been shown to achieve fast and high rates of cortisol normalization, improving manifestations of hypercortisolism in patients with Cushing’s Disease (CD), a form of CS. We evaluated relative complete response (CR) ou...

Objectives: Endogenous Cushing’s syndrome (CS) is a rare, chronic condition that results in high morbidity, caused by prolonged exposure to elevated levels of circulating free cortisol. A previous comparative analysis showed osilodrostat increases the odds of complete response (CR; mean urinary free cortisol [mUFC] ≤ 1.0 x the upper limit of normal) at Weeks 12 and 36 vs metyrapone1; however, analyses were limited by small osilodrostat effective sample si...